SPDL1 and central nervous system cancer: At baseline, sPD-L1 could be detected in 19/30 (63.3%) patients with GBM, whereas sPD-L1 could be found in the plasma of 8/10 (80.0%) patients with WHO grade II–III glioma (p = 0.451, Fisher’s exact test).